The launch of a handful of inventive cell and gene therapies is already testing players in the health care system to figure out how to pay for them. But the real strain could be five years away, when a wave of these pioneering treatments could enter the market and overwhelm the system.

That explains the growing pressure on drug companies, insurers, and others to develop value-based pricing — a mechanism to determine how much value any given therapy will provide over time.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy